Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Insights into the role of B cells in the cortical pathology of Multiple sclerosis: evidence from animal models and patients.

Authors:
Berenice Anabel Silva Esteban Miglietta Carina Cintia Ferrari

Mult Scler Relat Disord 2021 Feb 16;50:102845. Epub 2021 Feb 16.

Instituto de Medicina Traslacional e Ingeniería Biomédica (IMTIB), CONICET, Buenos Aires, Argentina; Leloir Institute Foundation, Institute for Biochemical Investigations, IIBBA, CONICET, Buenos Aires, Argentina. Electronic address:

Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system (CNS) that affects both white and gray matter. Although it has been traditionally considered as a T cell mediated disease, the role of B cell in MS pathology has become a topic of great research interest. Cortical lesions, key feature of the progressive forms of MS, are involved in cognitive impairment and worsening of the patients' outcome. These lesions present pathognomonic hallmarks, such as: absence of blood-brain barrier (BBB) disruption, limited inflammatory events, reactive microglia, neurodegeneration, demyelination and meningeal inflammation. B cells located in the meninges, either as part of diffuse inflammation or as part of follicle-like structures, are strongly associated with cortical damage. The function of CD20-expressing B cells in MS is further highlighted by the success of specific therapies using anti-CD20 antibodies. The possible roles of B cells in pathology go beyond their ability to produce antibodies, as they also present antigens to T cells, secrete cytokines (both pathogenic and protective) within the CNS to modulate T and myeloid cell functions, and are involved in meningeal inflammation. Here, we will review the contributions of B cells to the pathogenesis of meningeal inflammation and cortical lesions in MS patients as well as in preclinical animal models.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2021.102845DOI Listing
February 2021

Publication Analysis

Top Keywords

meningeal inflammation
12
cortical lesions
8
animal models
8
cells
6
cns modulate
4
worsening patients'
4
impairment worsening
4
follicle-like structures
4
cognitive impairment
4
roles cells
4
patients' outcome
4
pathogenic protective
4
pathognomonic hallmarks
4
lesions pathognomonic
4
protective cns
4
outcome lesions
4
modulate myeloid
4
myeloid cell
4
functions involved
4
key feature
4

Keyword Occurance

Similar Publications

Surface-in pathology in multiple sclerosis: a new view on pathogenesis?

Authors:
Matteo Pardini J William L Brown Roberta Magliozzi Richard Reynolds Declan T Chard

Brain 2021 Apr 20. Epub 2021 Apr 20.

NMR Research Unit, Queen Square Multiple Sclerosis Centre, University College London (UCL) Institute of Neurology, London, UK.

While multiple sclerosis can affect any part of the CNS, it does not do so evenly. In white matter it has long been recognized that lesions tend to occur around the ventricles, and grey matter lesions mainly accrue in the outermost (subpial) cortex. In cortical grey matter, neuronal loss is greater in the outermost layers. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Microglial changes associated with meningeal inflammation in multiple sclerosis.

Authors:
Heather Wood

Nat Rev Neurol 2021 Apr 12. Epub 2021 Apr 12.

Nature Reviews Neurology, .

View Article and Full-Text PDF
April 2021
Similar Publications

Cerebral amyloid angiopathy and related inflammatory disorders.

Authors:
B K Chwalisz

J Neurol Sci 2021 Mar 27:117425. Epub 2021 Mar 27.

Department of Neurology, Massachusetts General Hospital/Harvard Medical School, 15 Parkman Street, Suite 835, Boston, MA 02114, USA; Division of Neuro-Ophthalmology, Department of Ophthalmology, Massachusetts Eye & Ear Infirmary/Harvard Medical School, Boston, MA, USA. Electronic address:

Inflammatory cerebral amyloid angiopathy is a largely reversible inflammatory vasculopathy that develops in an acute or subacute fashion in reaction to amyloid protein deposition in the central nervous system blood vessels. There are two recognized pathologically characterized variants: cerebral amyloid angiopathy-related inflammation (CAAri) and A beta-related angiitis (ABRA). Both variants produce a clinical picture that resembles primary angiitis of the CNS but is distinguished by a characteristic radiologic appearance. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration.

Authors:
Lynn van Olst Carla Rodriguez-Mogeda Carmen Picon Svenja Kiljan Rachel E James Alwin Kamermans Susanne M A van der Pol Lydian Knoop Iliana Michailidou Evelien Drost Marc Franssen Geert J Schenk Jeroen J G Geurts Sandra Amor Nicholas D Mazarakis Jack van Horssen Helga E de Vries Richard Reynolds Maarten E Witte

Acta Neuropathol 2021 Mar 29. Epub 2021 Mar 29.

Department of Molecular Cell Biology and Immunology, Amsterdam UMC, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, Netherlands.

Meningeal inflammation strongly associates with demyelination and neuronal loss in the underlying cortex of progressive MS patients, thereby contributing significantly to clinical disability. However, the pathological mechanisms of meningeal inflammation-induced cortical pathology are still largely elusive. By extensive analysis of cortical microglia in post-mortem progressive MS tissue, we identified cortical areas with two MS-specific microglial populations, termed MS1 and MS2 cortex. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial).

Authors:
Mickael Bonnan Sylvie Ferrari Henri Courtade Paul Money Pauline Desblache Bruno Barroso Stéphane Debeugny

Mult Scler Int 2021 8;2021:8813498. Epub 2021 Mar 8.

Département de Recherche Clinique, Hôpital F. Mitterrand, 4 bd Hauterive, 64046 Pau, France.

Background: The progressive phase of multiple sclerosis (MS) is characterized by an intrathecal (IT) compartmentalization of inflammation, involving B-cells within meningeal follicles, and resisting all the available immunosuppressive treatments. A new therapeutic paradigm may be to target this inflammation by injecting immunosuppressive drugs inside the central nervous system compartment.

Methods: We designed a single-center, open-label, randomized, controlled, phase II study designed to evaluate the safety and efficacy of IT rituximab in progressive MS (EFFRITE trial; ClinicalTrial Registration NCT02545959). Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap